



**PRESS RELEASE**

## **Amoeba raises EUR 14,693,805 million from European and US investors**

- Private placement of 544,215 new ordinary shares with a par value of 0.02 €, corresponding to the maximum number authorized by the management board (*Directoire*)
- This investment will help accelerate Amoéba's industrial development plan, allowing to install 4 production bioreactors on its site in Chassieu a year ahead of schedule

**Lyon, May 13, 2016 – – AMOEBA (FR0011051598 - AMEBA)**, producer of a biological biocide capable of eliminating waterborne bacterial risks (the “Company”), announces today the successful completion of a private placement of a total amount of approximately EUR 14.7 million.

### **Terms of the private placement**

A total of 544,215 new ordinary shares, par value EUR 0.02 each, have been issued to qualified and institutional investors in the United States and Europe pursuant to resolution 25 of the combined general meeting of the shareholders of the Company held on April 7, 2015. The new ordinary shares have been issued with European and American investors, of which two third are from France and one third are aboard. The new shares represent approximately 10% of the outstanding Company shares prior to the private placement.

The private placement was conducted by way of an accelerated book building in accordance with article L. 411-2 II.2 of the French Monetary and Financial Code (*code monétaire et financier*).

The issue price of the new shares had been set at EUR 27 per share, representing a 16.21% discount to the weighted average stock price over the last three trading days immediately preceding today (May 10, 2016 - May 12, 2016 inclusive), which was EUR 32.2251, pursuant to resolution 27 of the combined general meeting of the shareholders of the Company held on April 7, 2015.

*“I am pleased to announce the success of a new fundraising campaign which confirms the confidence our current investors and high-ranking international investors have in our product. This investment will help accelerate Amoéba's industrial development plan, allowing us to install 4 production bioreactors on our site in Chassieu a year ahead of schedule.*

*The arrival of US investors lends legitimacy to Amoéba's development strategy in North American territories, where the Company already has a production unit in Montreal.”* indicated Fabrice PLASSON, President of the board of directors of Amoeba.

### **Use of proceeds**

The net proceeds from the transaction will be used primarily for financing: i) the acceleration of operations in Europe following (a) the deployment of two production units each producing 500 liters and (b) the development of the North American market through the implementation of a production unit in order to facilitate, in particular, the completion of the research and development (R&D) tests in Canada, and ii) general corporate expenses.

### **Listing of the new shares**

The Company's new shares are expected to be admitted to trading on the regulated market of Euronext in Paris on May 17, 2016. They will be listed under the same code as the existing shares (ISIN FR0011051598) and will carry dividend rights as from their issue date and be immediately fungible in all respects with the Company's existing shares.

The private placement is not subject to a prospectus to be approved by the French financial markets authority (*Autorité des marchés financiers* – the “**AMF**”).

### **Information available to the public**

Additional information about the Company, including its business, financial information, perspective and risk factors on its business and activities can be found in the *document de référence* registered by the AMF on April 27, 2016 under the number R. 16-029, which is available free of charge at the headquarters of the Company, 38, avenue des frères Montgolfier, 69680 Chassieu, France, and on the Company's website ([www.ameoba-biocide.com](http://www.ameoba-biocide.com)) and the AMF website ([www.amf-france.org](http://www.amf-france.org)).

Bryan Garnier & Co acted as Global Coordinator, Lead Manager and Joint Bookrunner, and Portzamparc Société de Bourse, as Joint Bookrunner and Lead Manager in the private placement.



**About AMOEBA:** Based in Chassieu – France, AMOEBA develops a biological biocide capable of eliminating waterborne bacterial risk (legionella, pseudomonas, listeria, etc.) This entirely natural solution is presented as an alternative to the chemical treatments traditionally used in the industrial sector. AMOEBA is continuing with its regulatory procedures so as to launch the request for provisional MA in the first half of 2016 for all European countries, as soon as ANSES (French Agency for Food, Environmental and Occupational Health & Safety) has validated AMOEBA's solution for the “Air Cooled Towers” application. In a worldwide market for chemical biocides, estimated to be worth EUR 21 bn<sup>(1)</sup>, AMOEBA is today concentrating on the segment of industrial air-cooled towers (ACT) estimated to be worth EUR 1.7 bn<sup>(2)</sup>. Its disruptive technology complies with new regulations in terms of chemical emissions into the environment.

AMOEBEA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC Small index last September 21. For more information: [www.amoeba-biocide.com](http://www.amoeba-biocide.com).

(1): Sources combined by Amoeba from water treatment agencies, Freedonia, Eurostat and MarketsandMarkets

(2): Amoeba data combined from the following sources: DRIRE 2013, Eurostat, ARHIA 2013

### **Contacts :**

Amoéba

Christine GENDROT LAURAIN

Responsable Communication

06 62 10 83 70

[christine.laurain@amoeba-biocide.com](mailto:christine.laurain@amoeba-biocide.com)

Actifin

Ghislaine GASPARETTO

Communication financière

01 56 88 11 11

[ggasparetto@actifin.fr](mailto:ggasparetto@actifin.fr)

### **Disclaimer**

*The offering does not constitute a public offering in France, as defined in Article L. 411-1 of the French Monetary and Financial Code (code monétaire et financier) and no prospectus reviewed or approved by the AMF will be published. This press release is for information purposes only and does not, and shall not, in any circumstances, constitute a public offering by Amoeba nor a solicitation of an offer to subscribe for securities in any jurisdiction, including France.*

*With respect to Member States of the European Economic Area that have transposed European Directive 2003/71/EC of the European Parliament and European Council (as amended, in particular by Directive 2010/73/EU to the extent that the said Directive has been transposed into each Member State of the European Economic Area) (the "Prospectus Directive"), no action has been taken or will be taken to permit a public offering of the securities referred to in this press release which would require the publication of a prospectus in any Member State.*

*This press release and the information it contains is not an offer to subscribe for or sell, nor the solicitation of an offer to subscribe for or buy, shares of Amoeba in the United States or any other jurisdiction where restrictions may apply. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. Amoeba does not intend to register securities or conduct a public offering in the United States, or in any other jurisdiction.*

*In the United Kingdom, this document is only being distributed to, and is only directed at, persons that are "qualified investors" within the meaning of Article 2(1)(e)(i), (ii) or (iii) of the Prospectus Directive and that also (i) are "investment professionals" falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). In the United Kingdom, this press release is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this press release relates is available only to relevant persons and will be engaged in only with relevant persons.*

*This distribution of this press release may be subject to legal or regulatory restrictions in certain jurisdictions. Any person who comes into possession of this press release must inform him or herself of and comply with any such restrictions.*

*This press release shall not be published, provided nor submitted, directly or indirectly, in or into the United States, South Africa, Canada, Australia or Japan.*

**Forward-looking Information**

*This press release contains certain forward-looking statements concerning Amoeba and its business, including the Company's strategy and plans for the Company's products. Such forward-looking statements are, by their nature, subject to a number of important risks and uncertainties, and actual results, financial conditions, performance or achievements of Amoeba may be materially different from the plans, objectives and expectations expressed or implied in such forward-looking statements. Forward-looking statements speak only as of the date on which they are made, and Amoeba undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.*